Prudential Financial’s Avidity Biosciences RNAM Stock Holding History

Prudential Financial’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,060	Closed	-$509K	–	2498
2025 Q4	$509K	Sell	7,060 -77,805	-92%	-$5.03M	﹤0.01%	1823
2025 Q3	$3.7M	Sell	84,865 -28,140	-25%	-$1.14M	﹤0.01%	1078
2025 Q2	$3.21M	Sell	113,005 -43,625	-28%	-$1.3M	﹤0.01%	1144
2025 Q1	$4.62M	Buy	156,630 +145,750	+1,340%	+$4.54M	0.01%	870
2024 Q4	$316K	Sell	10,880 -3,500	-24%	-$146K	﹤0.01%	1976
2024 Q3	$660K	Sell	14,380 -8,910	-38%	-$387K	﹤0.01%	2094
2024 Q2	$951K	Sell	23,290 -4,790	-17%	-$137K	﹤0.01%	1857
2024 Q1	$717K	Buy	+28,080	New	+$440K	﹤0.01%	2004

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

Prudential Financial's RNAM Position: Q1 2026 in Review

Prudential Financial sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 7,060 shares — an estimated $509K sold.

Prudential Financial first reported a position in RNAM in Q1 2024 and held it in 8 quarters. The position peaked at $4.62M in Q1 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

Prudential Financial reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
Prudential Financial sold 7,060 Avidity Biosciences shares in Q1 2026, an estimated $509K.
Prudential Financial first reported a position in Avidity Biosciences in Q1 2024 and held it in 8 quarters.
Prudential Financial's Avidity Biosciences position peaked at $4.62M in Q1 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.